Pádraig O'Sullivan (Cork North-Central, Fianna Fail)

Clinical trials were mentioned. One of the things that has defined my outlook on reimbursement, which the witnesses may have gauged from earlier discussions, was a meeting Deputy Lahart and I had with a group of public servants from Denmark who set up an ad hoc rare disease committee a number of years ago. They came here to learn about how Ireland is the leader in terms of manufacturing, workforce, corporation tax investment, foreign direct investment and all of that. They came to take learnings from us on that side of the matter. However, when we sat down with them afterwards and spoke about our processes in terms of reimbursement, clinical trials and so on, they were kind of gobsmacked at where they were compared with us. As I said, that meeting has defined my outlook on how we should do things here. There is a target in the national cancer strategy to increase access for patients to clinical trials from the current 2% or 3% to 6%. How are we to bridge that gap?